TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35972667

Group type: EXPERIMENTAL
Intervention: Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin/mitomycin C
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cytoreduction and HIPEC
Number of subjects: 18
Study: 35972787

Group type: EXPERIMENTAL
Intervention: Web-based intervention including a health literacy (HL) module and 3 obesity prevention modules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Web-based intervention including a vaping module and 3 obesity prevention modules
Number of subjects: 0
Study: 35972987

Group type: EXPERIMENTAL
Intervention: Inhaled Galectin-3 Inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35973031

Group type: EXPERIMENTAL
Intervention: Empagliflozin, dosage and duration not available
Number of subjects: 0
Study: 35973148

Group type: EXPERIMENTAL
Intervention: 96-hour wireless pH monitoring off PPI
Number of subjects: 132
Study: 35973149

Group type: EXPERIMENTAL
Intervention: Detection of anti-HEV IgG
Number of subjects: 2012

Group type: EXPERIMENTAL
Intervention: Testing for anti-HEV IgM and HEV RNA
Number of subjects: 2012

Group type: EXPERIMENTAL
Intervention: Incidence of acute hepatitis E
Number of subjects: 2012

Group type: EXPERIMENTAL
Intervention: Overall prevalence of anti-HEV
Number of subjects: 2012

Group type: EXPERIMENTAL
Intervention: Acute HEV infection in suspected DILI cases
Number of subjects: 2012
Study: 35973168

Group type: EXPERIMENTAL
Intervention: SAVE score
Number of subjects: 197
Study: 35973190

Group type: EXPERIMENTAL
Intervention: Sutimlimab (biweekly administration for a median of 20.5 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sutimlimab (retreatment for a median of 113 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sutimlimab
Number of subjects: 12
Study: 35973192

Group type: EXPERIMENTAL
Intervention: tisagenlecleucel (tisa-cel)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 285
Study: 35973199

Group type: EXPERIMENTAL
Intervention: Combination of enasidenib with azacitidine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Enasidenib monotherapy after prior hypomethylating agent (HMA) therapy
Number of subjects: 50
Study: 35973200

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks for up to 2 years)
Number of subjects: 12
Study: 35973665

Group type: EXPERIMENTAL
Intervention: Pralsetinib 400 mg once daily until disease progression, intolerance, consent withdrawal, or investigator's decision.
Number of subjects: 281
Study: 35973700

Group type: EXPERIMENTAL
Intervention: Patient-controlled admissions (PCA)
Number of subjects: 45
Study: 35973737

Group type: EXPERIMENTAL
Intervention: Dostarlimab (500 mg IV every 3 weeks for 4 cycles, then 1000 mg IV every 6 weeks)
Number of subjects: 88
Study: 35973801

Group type: EXPERIMENTAL
Intervention: NT-proBNP levels in obese patients (BMI ≥ 30) during pregnancy
Number of subjects: 55

Group type: COMPARATOR
Intervention: NT-proBNP levels in nonobese patients (BMI < 30) during pregnancy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: NT-proBNP levels in obese patients (BMI ≥ 30) postpartum (up to 4 to 6 weeks)
Number of subjects: 55

Group type: COMPARATOR
Intervention: NT-proBNP levels in nonobese patients (BMI < 30) postpartum (up to 4 to 6 weeks)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Hypertensive disorders of pregnancy in obese patients (BMI ≥ 30)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Hypertensive disorders of pregnancy in nonobese patients (BMI < 30)
Number of subjects: 55
Study: 35973887

Group type: EXPERIMENTAL
Intervention: GI-extended FFQ
Number of subjects: 100
Study: 35974101

Group type: EXPERIMENTAL
Intervention: Rituximab monotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: R-CHOP-21
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alternating R-CHOP-21 and modified R-DHAOx
Number of subjects: 60

Group type: COMPARATOR
Intervention: Historical comparator (CHOP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall response
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2-year time to progression
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2-year overall survival (OS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2-year OS in low-risk group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Treatment-related mortality
Number of subjects: 60
Study: 35974168

Group type: EXPERIMENTAL
Intervention: Palbociclib combined with endocrine therapy (ET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endocrine therapy (ET) only
Number of subjects: 0
Study: 35974320

Group type: EXPERIMENTAL
Intervention: Early menopause (40-44 years)
Number of subjects: 18326

Group type: EXPERIMENTAL
Intervention: Self-reported weight loss since age 20
Number of subjects: 18326

Group type: COMPARATOR
Intervention: Daily alcohol consumption in the third quartile (5.36-11.42 g/day)
Number of subjects: 18326

Group type: EXPERIMENTAL
Intervention: Increasing age and weight at baseline, current smoking, positive history of previous fracture, family history of fractures
Number of subjects: 18326

Group type: EXPERIMENTAL
Intervention: Increasing BMI
Number of subjects: 18326
Study: 35974328

Group type: EXPERIMENTAL
Intervention: Indigenous Healing and Seeking Safety (IHSS)
Number of subjects: 402

Group type: COMPARATOR
Intervention: No IHSS
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: IHSS
Number of subjects: 402
Study: 35974326

Group type: EXPERIMENTAL
Intervention: Gynecological surgery (benign conditions)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Gynecological surgery (malignant conditions)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Higher resilience
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Preoperative evaluation for low resilience
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Anxiety and life satisfaction measures
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Depression measures
Number of subjects: 271
Study: 35974422

Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Number of subjects: 118
Study: 35974874

Group type: EXPERIMENTAL
Intervention: Natural procreative technology treatment
Number of subjects: 834
Study: 35974896

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antibodies testing
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Infection prevention measures (proper use of alcohol-based hand rub, soap and water, wearing PPE)
Number of subjects: 682
Study: 35975199

Group type: EXPERIMENTAL
Intervention: Multiplexed, baited, targeted proteomics assay for detection of SARS-CoV-2 anti-spike antibody immunocomplex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard ELISA-based serology
Number of subjects: 0
Study: 35975210

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GLP-1RAs
Number of subjects: 0
Study: 35975738

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin combined with ifosfamide-carboplatin-etoposide (BV-ICE)
Number of subjects: 52
Study: 35976085

Group type: EXPERIMENTAL
Intervention: ISIS 353512 targeting human C-reactive protein (CRP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroquine pretreatment of PBMCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discriminator donor PBMCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PBMC assay using discriminator donors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Known benchmark ASO controls
Number of subjects: 0
Study: 35976192

Group type: EXPERIMENTAL
Intervention: 12 weeks of virtual reality tele-exergaming intervention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 34
Study: 35976232

Group type: EXPERIMENTAL
Intervention: Retinal vascular bed area (RVBA) in eyes with RVO
Number of subjects: 30

Group type: COMPARATOR
Intervention: Retinal vascular bed area (RVBA)
Number of subjects: 30
Study: 35976252

Group type: EXPERIMENTAL
Intervention: ILM peeling
Number of subjects: 42

Group type: COMPARATOR
Intervention: ILM nonpeeling
Number of subjects: 42
Study: 35976282

Group type: EXPERIMENTAL
Intervention: Crohn Disease Exclusion Diet (CDED)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Free diet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Baseline microbiome analysis
Number of subjects: 18
Study: 35976415

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 71
Study: 35976570

Group type: EXPERIMENTAL
Intervention: Brensocatib 10 mg
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Brensocatib 25 mg
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Brensocatib (10 mg and 25 mg)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Brensocatib
Number of subjects: 241
Study: 35976603

Group type: EXPERIMENTAL
Intervention: Esaxerenone monotherapy (2.5 or 5 mg/day)
Number of subjects: 25
Study: 35977080

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 251
Study: 35977104

Group type: EXPERIMENTAL
Intervention: Extended match time (90 + 30 min)
Number of subjects: 20
Study: 35977103

Group type: EXPERIMENTAL
Intervention: Substituting sedentary time with vigorous-intensity physical activity
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Substituting sedentary time with sleep
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Substituting sedentary time with moderate- to vigorous-intensity physical activity
Number of subjects: 217
Study: 35977357

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 0
Study: 35977366

Group type: EXPERIMENTAL
Intervention: Bloodless care
Number of subjects: 1111

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1111

Group type: EXPERIMENTAL
Intervention: Bloodless care (medical subgroup)
Number of subjects: 1111

Group type: COMPARATOR
Intervention: Standard care (medical subgroup)
Number of subjects: 1111
Study: 35977396

Group type: EXPERIMENTAL
Intervention: Percentage mother's milk intake during hospitalization
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: DNAm at several top identified CpGs from the EWAS
Number of subjects: 143
Study: 35977532

Group type: EXPERIMENTAL
Intervention: Hydroxyurea at 20 mg/kg/day with dose escalation to maximum tolerated dose (MTD)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment
Number of subjects: 202
Study: 35977756

Group type: EXPERIMENTAL
Intervention: Nivolumab plus rucaparib (nivolumab 480 mg every 4 weeks plus rucaparib 600 mg two times per day)
Number of subjects: 0
Study: 35977762

Group type: EXPERIMENTAL
Intervention: Long-acting (LA) injectable PrEP
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Oral pills
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: PrEP (general)
Number of subjects: 293
Study: 35977832

Group type: EXPERIMENTAL
Intervention: PWWE
Number of subjects: 331

Group type: COMPARATOR
Intervention: HPW
Number of subjects: 331

Group type: COMPARATOR
Intervention: NPWWE
Number of subjects: 331
Study: 35977881

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPI)
Number of subjects: 707

Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 707
Study: 35977936

Group type: EXPERIMENTAL
Intervention: PRV111 (neoadjuvant treatment)
Number of subjects: 0
Study: 35978373

Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 411
Study: 35978394

Group type: EXPERIMENTAL
Intervention: Active tAN
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Active tAN (Group 1)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham tAN (Group 2)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Active tAN (Days 2-5)
Number of subjects: 31
Study: 35978403

Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test (FIT)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Highest value of two FIT at cutoff 10 μg Hb/g faeces
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Reference test linked to the Swedish Colorectal Cancer Registry
Number of subjects: 3000
Study: 35979021

Group type: EXPERIMENTAL
Intervention: Biodegradable nitride iron stents (IBS)
Number of subjects: 11
Study: 35979039

Group type: COMPARATOR
Intervention: Elevated PTSD symptoms
Number of subjects: 635

Group type: COMPARATOR
Intervention: Alcohol or cannabis comorbidity
Number of subjects: 635

Group type: COMPARATOR
Intervention: Stimulant comorbidity
Number of subjects: 635

Group type: COMPARATOR
Intervention: Opioid comorbidity
Number of subjects: 635
Study: 35979886

Group type: EXPERIMENTAL
Intervention: Analytical treatment interruption (ATI) during the HIV cure-directed trial
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Motivations for trial participation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Support systems for trial enrollment decision
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Understanding of trial procedures
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Concerns regarding ATI
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Excitement for trial participation
Number of subjects: 15
Study: 35980235

Group type: EXPERIMENTAL
Intervention: osilodrostat (starting dose 2 mg bid; maximum 30 mg bid)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: osilodrostat
Number of subjects: 137
Study: 35980739

Group type: EXPERIMENTAL
Intervention: Lumme Quit Smoking app and smartwatch combination
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control arm with 8-week supply of nicotine replacement therapy, 30-minute smoking cessation counseling session, and weekly check-in calls
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both arms together (intervention and control)
Number of subjects: 40
Study: 35981452

Group type: EXPERIMENTAL
Intervention: Radium-223
Number of subjects: 52
Study: 35981626

Group type: EXPERIMENTAL
Intervention: Fortnightly questionnaires assessing anxiety, depression, and stress
Number of subjects: 211

Group type: COMPARATOR
Intervention: Reassignment of healthcare workers
Number of subjects: 211
Study: 35981784

Group type: EXPERIMENTAL
Intervention: Skin carotenoid score (SCS) measurement using reflection spectroscopy (RS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Skin carotenoid score (SCS) measurement using reflection spectroscopy (RS) in 8-month-olds
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Skin carotenoid score (SCS) measurement using reflection spectroscopy (RS) in 6-month-olds
Number of subjects: 21
Study: 35981916

Group type: EXPERIMENTAL
Intervention: Visualized fibroid at any time during pregnancy
Number of subjects: 2774

Group type: EXPERIMENTAL
Intervention: Total fibroid volume change
Number of subjects: 2774

Group type: EXPERIMENTAL
Intervention: Total fibroid volume change for small volume
Number of subjects: 2774

Group type: EXPERIMENTAL
Intervention: Total fibroid volume change for medium volume
Number of subjects: 2774

Group type: EXPERIMENTAL
Intervention: Total fibroid volume change for large volume
Number of subjects: 2774

Group type: EXPERIMENTAL
Intervention: Visualized fibroid number change
Number of subjects: 2774

Group type: EXPERIMENTAL
Intervention: Total fibroid volume change by race/ethnicity
Number of subjects: 2774
Study: 35981917

Group type: EXPERIMENTAL
Intervention: Retinal arteriolar caliber and retinal venular curvature tortuosity
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Retinal curvature tortuosity (per SD increase)
Number of subjects: 456
Study: 35982228

Group type: EXPERIMENTAL
Intervention: Good pain control under analgesic treatment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: No or minor pain
Number of subjects: 80

Group type: COMPARATOR
Intervention: Poor pain control despite analgesic treatment
Number of subjects: 80
Study: 35982244

Group type: EXPERIMENTAL
Intervention: Maternal voice exposure (twice daily for 20 minutes before oral feeding)
Number of subjects: 25
Study: 35982396

Group type: EXPERIMENTAL
Intervention: Functional connectivity of the right and left antero-dorsal insula in MA patients.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Functional connectivity analysis using seed-to-voxel analysis in MA patients.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Comparison of functional connectivity in MA patients versus MO patients.
Number of subjects: 21
Study: 35982403

Group type: EXPERIMENTAL
Intervention: Carina-distal (C-D) group
Number of subjects: 168

Group type: COMPARATOR
Intervention: Carina-proximal (C-P) group
Number of subjects: 168

Group type: COMPARATOR
Intervention: Carina-carina (C-C) group
Number of subjects: 168
Study: 35982410

Group type: EXPERIMENTAL
Intervention: Higher preoperative serum PGE2 levels
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Higher preoperative serum neurofilament light levels
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Lower preoperative MMSE scores
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 131
Study: 35982424

Group type: EXPERIMENTAL
Intervention: Higher rates of depression
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Negative attitudes to aging
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Visual impairment (in men)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Lowered self-sufficiency in ADL (in women)
Number of subjects: 316
Study: 35982495

Group type: EXPERIMENTAL
Intervention: Serum TMAO (tertiles)
Number of subjects: 2088

Group type: EXPERIMENTAL
Intervention: Highest tertile of serum TMAO
Number of subjects: 2088

Group type: EXPERIMENTAL
Intervention: Serum TMAO
Number of subjects: 2088
Study: 35982649

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone furoate 200 μg once daily for 14 days
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone furoate
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 1277
Study: 35982669

Group type: EXPERIMENTAL
Intervention: Ivermectin 400 µg/kg daily for 3 days
Number of subjects: 1591

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1591
Study: 35982675

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 35983024

Group type: EXPERIMENTAL
Intervention: Apatinib (250 mg once daily) combined with docetaxel (IV every 3 weeks for four cycles) followed by epirubicin plus cyclophosphamide (IV every 3 weeks for four cycles)
Number of subjects: 31
Study: 35983025

Group type: EXPERIMENTAL
Intervention: AS (Nab-paclitaxel plus S-1)
Number of subjects: 97

Group type: COMPARATOR
Intervention: SOX (not explicitly defined in the abstract)
Number of subjects: 97
Study: 35983090

Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy (TBCB)
Number of subjects: 216
Study: 35983177

Group type: EXPERIMENTAL
Intervention: Cerene Cryotherapy Device treatment
Number of subjects: 242
Study: 35983269

Group type: EXPERIMENTAL
Intervention: Initial moderate or severe acute illness
Number of subjects: 289

Group type: COMPARATOR
Intervention: Initial mild acute illness
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 289
Study: 35983331

Group type: EXPERIMENTAL
Intervention: mNGS-guided treatment
Number of subjects: 342

Group type: COMPARATOR
Intervention: Conventional treatment (guided by CMT)
Number of subjects: 342
Study: 35983405

Group type: EXPERIMENTAL
Intervention: Quarterly ECG screening for atrial fibrillation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Annual ECG screening for atrial fibrillation
Number of subjects: 0
Study: 35983606

Group type: EXPERIMENTAL
Intervention: Online group intervention for parents (two sessions, one week apart, via videoconferencing)
Number of subjects: 32
Study: 35984091

Group type: EXPERIMENTAL
Intervention: Operative treatment (n = 88; 31%)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Nonoperative treatment (control group)
Number of subjects: 282
Study: 35984529

Group type: EXPERIMENTAL
Intervention: Diagnostic evaluation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 30
Study: 35984611

Group type: EXPERIMENTAL
Intervention: Heparin-like effect (HLE) defined as ≥ 20% difference in paired gb/h-SONOCLOT™ traces for activated clotting time (ACT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Factor XIII levels
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Factor VII levels
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: gbACT > 252 s
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: hACT > 215 s
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: HLE > 50%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Baseline Factor VIII
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low Factor VII
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lysis
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Endogenous heparinoids at baseline
Number of subjects: 90
Study: 35984695

Group type: EXPERIMENTAL
Intervention: SCI Step Together mobile health intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilot testing of the app by three end users
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavior Change Wheel techniques included in the app
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of SCI IKT Guiding Principles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Future research plans
Number of subjects: 0
Study: 35984700

Group type: EXPERIMENTAL
Intervention: 12-month multifaceted implementation strategy for a healthy lifestyle-promoting practice in PHC.
Number of subjects: 500
Study: 35984996

Group type: EXPERIMENTAL
Intervention: sEphB4-HSA + pembrolizumab
Number of subjects: 70
Study: 35985786

Group type: EXPERIMENTAL
Intervention: Density of non-residential destinations (NRDs) within 1 km of home address
Number of subjects: 2405
Study: 35986100

Group type: EXPERIMENTAL
Intervention: Emotional support from other family
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Alcohol/drug use
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Taking care of others
Number of subjects: 833